

# Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2020

<https://marketpublishers.com/r/C33A165199DEN.html>

Date: April 2020

Pages: 552

Price: US\$ 2,000.00 (Single User License)

ID: C33A165199DEN

## Abstracts

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Obstructive Pulmonary Disease - Pipeline Review, H1 2020, provides an overview of the Chronic Obstructive Pulmonary Disease (Respiratory) pipeline landscape.

Chronic obstructive pulmonary disease (COPD) is a group of lung diseases. It is characterized by inability to completely breathe out air from the lungs leading to shortness of breath. The airflow to the lungs is further blocked. Other symptoms include cough, fatigue and chest pain. The disease tends to worsen over the time hence increasing the complications. The risk factors involved in causing COPD include smoking as the primary reason. Exposure to chemicals and air pollution also contribute in the development of COPD.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Obstructive Pulmonary Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Obstructive Pulmonary Disease (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 8, 38, 15, 3, 77, 21 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 2 molecules, respectively.

Chronic Obstructive Pulmonary Disease (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Obstructive Pulmonary Disease (Respiratory).

The pipeline guide reviews pipeline therapeutics for Chronic Obstructive Pulmonary Disease (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Chronic Obstructive Pulmonary Disease (Respiratory) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Chronic Obstructive Pulmonary Disease (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Obstructive Pulmonary Disease (Respiratory)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Chronic Obstructive Pulmonary Disease (Respiratory).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (Respiratory) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Chronic Obstructive Pulmonary Disease (COPD) - Overview

Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Development

Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Assessment

Chronic Obstructive Pulmonary Disease (COPD) - Companies Involved in Therapeutics Development

Chronic Obstructive Pulmonary Disease (COPD) - Drug Profiles

Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects

Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products

Chronic Obstructive Pulmonary Disease (COPD) - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..6), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Products under Development by Companies, H1 2020 (Contd..5), H1 2020

Products under Development by Companies, H1 2020 (Contd..6), H1 2020

Products under Development by Companies, H1 2020 (Contd..7), H1 2020

Products under Development by Companies, H1 2020 (Contd..8), H1 2020

Products under Development by Companies, H1 2020 (Contd..9), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by 3SBio Inc, H1 2020

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AB Science SA, H1 2020

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AB2 Bio Ltd, H1 2020

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Adamis Pharmaceuticals

Corp, H1 2020

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Afimmune Biopharma Ltd, H1 2020

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Aibios Co Ltd, H1 2020

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AlgiPharma AS, H1 2020

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Allinaire Therapeutics LLC, H1 2020

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Amgen Inc, H1 2020

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Angiocrine Bioscience Inc, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

3SBio Inc

AB Science SA

AB2 Bio Ltd

Adamis Pharmaceuticals Corp

Afimmune Biopharma Ltd

Aibios Co Ltd

AlgiPharma AS

Allinaire Therapeutics LLC

Amgen Inc

Angiocrine Bioscience Inc

Apollo Therapeutics LLC

Aquilon Pharmaceuticals SA

Aridis Pharmaceuticals Inc

Ark Biosciences Inc

AstraZeneca Plc

AusBio Ltd

Avidin Ltd

Axolo Pharma Inc

Bai Shuo Beijing Pharmaceutical Technology Co Ltd

Bayer AG



BioMarck Pharmaceuticals Ltd  
Boehringer Ingelheim International GmbH  
C4X Discovery Holdings Plc  
Cambryn Biologics LLC  
Celon Pharma SA  
Chiesi Farmaceutici SpA  
China Resources Pharmaceutical Group Ltd  
Cipla Ltd  
Circassia Pharmaceuticals Plc  
Covenant Therapeutics LLC  
CSL Ltd  
Cureveda LLC  
Cytokinetics Inc  
Daewoong Pharmaceutical Co Ltd  
Denovo Biopharma LLC  
Diffusion Pharmaceuticals Inc  
Dimerix Ltd  
Domainex Ltd  
EmeraMed Ltd  
EmphyCorp Inc  
Emphymab Biotech LLC  
Enzychem Lifesciences Corp  
EpiEndo Pharmaceuticals Ehf  
EpiTracker Inc  
Errant Gene Therapeutics LLC  
ethris GmbH  
Evaxion Biotech ApS  
Exotect LLC  
F. Hoffmann-La Roche Ltd  
Foresee Pharmaceuticals Co Ltd  
Future Medicine Co Ltd  
Galapagos NV  
GeneFrontier Corp  
Gilead Sciences Inc  
GlaxoSmithKline Plc  
Glenmark Pharmaceuticals Ltd  
Grifols SA  
iCeutica Inc  
Icure Pharmaceutical Inc

InMed Pharmaceuticals Inc  
Inmunotek SL  
Insmed Inc  
Invion Ltd  
Ionis Pharmaceuticals Inc  
JiangSu Qyuns Therapeutics Co Ltd  
Johnson & Johnson  
KBP BioSciences Co Ltd  
Kither Biotech Srl  
Korea United Pharm Inc  
Koutif Therapeutics LLC  
Kyowa Kirin Co Ltd  
LTT Bio-Pharma Co Ltd  
Mariposa Health Ltd  
MD Healthcare Inc  
Mereo Biopharma Group Plc  
Meridigen Biotech Co Ltd  
Metagone Biotech Inc  
MetrioPharm AG  
Naegis Pharmaceuticals Inc  
NB Health Laboratory Co Ltd  
Novabiotics Ltd  
Novartis AG  
Omnispirant Ltd  
OncoArendi Therapeutics SA  
Oncostellae SL  
Orchid Pharma Ltd  
Orphomed Inc  
Palo BioFarma SL  
PharmaLundensis AB  
Pharmaxis Ltd  
Prous Institute for Biomedical Research SA  
Pulmatrix Inc  
Pulmotect Inc  
Qu Biologics Inc  
Quark Pharmaceuticals Inc  
Re-Pharm Ltd  
Regeneron Pharmaceuticals Inc  
Resolys Bio Inc

Respiratorius AB  
Rhizen Pharmaceuticals SA  
Santhera Pharmaceuticals Holding AG  
Silurian Pharmaceuticals Inc  
Silver Valley Pharmaceutical Co Ltd  
SolAeroMed Inc  
Sparrow Pharmaceuticals Inc  
sterna biologicals Gmbh & Co KG  
Sulfateq BV  
Suzhou Connect Biopharmaceuticals Ltd  
Symmune Therapeutics LLC  
Synairgen Plc  
Synovo GmbH  
Syntrix Biosystems Inc  
Taiho Pharmaceutical Co Ltd  
Teva Pharmaceutical Industries Ltd  
TFF Pharmaceuticals Inc  
TGV-Inhalonix Inc  
Theratrophix LLC  
Torrent Pharmaceuticals Ltd  
Unity Biotechnology Inc  
Verona Pharma Plc  
Verra Therapeutics LLC  
Vicenna Pharmaceuticals Inc  
vTv Therapeutics Inc  
Yungjin Pharm Co Ltd  
Zai Lab Ltd

## I would like to order

Product name: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/C33A165199DEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C33A165199DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970